536 related articles for article (PubMed ID: 30243478)
1. Precision medicine and bladder cancer heterogeneity.
Ma G; Yang X; Liang Y; Wang L; Li D; Chen Y; Liang Z; Wang Y; Niu H
Bull Cancer; 2018 Oct; 105(10):925-931. PubMed ID: 30243478
[TBL] [Abstract][Full Text] [Related]
2. Clinical Proteomics for Precision Medicine: The Bladder Cancer Case.
Latosinska A; Frantzi M; Vlahou A; Merseburger AS; Mischak H
Proteomics Clin Appl; 2018 Mar; 12(2):. PubMed ID: 28980455
[TBL] [Abstract][Full Text] [Related]
3. Bladder Tumor Heterogeneity: The Impact on Clinical Treatment.
Chen C; Qi XJ; Cao YW; Wang YH; Yang XC; Shao SX; Niu HT
Urol Int; 2015; 95(1):1-8. PubMed ID: 25823547
[TBL] [Abstract][Full Text] [Related]
4. Unmasking molecular profiles of bladder cancer.
Piao XM; Byun YJ; Kim WJ; Kim J
Investig Clin Urol; 2018 Mar; 59(2):72-82. PubMed ID: 29520382
[TBL] [Abstract][Full Text] [Related]
5. A place for precision medicine in bladder cancer: targeting the FGFRs.
di Martino E; Tomlinson DC; Williams SV; Knowles MA
Future Oncol; 2016 Oct; 12(19):2243-63. PubMed ID: 27381494
[TBL] [Abstract][Full Text] [Related]
6. Toward personalized management in bladder cancer: the promise of novel molecular taxonomy.
Eich ML; Dyrskjøt L; Netto GJ
Virchows Arch; 2017 Aug; 471(2):271-280. PubMed ID: 28429075
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma.
Zhong L; Liu Y; Wang K; He Z; Gong Z; Zhao Z; Yang Y; Gao X; Li F; Wu H; Zhang S; Chen L
BMC Cancer; 2018 Sep; 18(1):911. PubMed ID: 30241505
[TBL] [Abstract][Full Text] [Related]
8. Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy.
Stakheyeva M; Riabov V; Mitrofanova I; Litviakov N; Choynzonov E; Cherdyntseva N; Kzhyshkowska J
Curr Pharm Des; 2017; 23(32):4807-4826. PubMed ID: 28714406
[TBL] [Abstract][Full Text] [Related]
9. Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine.
Nössing C; Herek P; Shariat SF; Berger W; Englinger B
Curr Opin Urol; 2024 Jul; 34(4):251-257. PubMed ID: 38602053
[TBL] [Abstract][Full Text] [Related]
10. A precision, personalized approach to the management of bladder cancer.
Apolo AB; Burger M
Curr Opin Urol; 2015 Sep; 25(5):416-7. PubMed ID: 26153639
[No Abstract] [Full Text] [Related]
11. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy.
Wu D; Wang DC; Cheng Y; Qian M; Zhang M; Shen Q; Wang X
Semin Cancer Biol; 2017 Feb; 42():13-19. PubMed ID: 27840278
[TBL] [Abstract][Full Text] [Related]
12. New strategies in muscle-invasive bladder cancer: on the road to personalized medicine.
Shah JB; McConkey DJ; Dinney CP
Clin Cancer Res; 2011 May; 17(9):2608-12. PubMed ID: 21415213
[TBL] [Abstract][Full Text] [Related]
13. Genotypic and phenotypic biomarker profiles for individual risk assessment and cancer detection (lessons from bladder cancer risk assessment in symptomatic patients and workers exposed to benzidine).
Hemstreet GP; Wang W
Front Biosci; 2004 Sep; 9():2671-9. PubMed ID: 15358590
[TBL] [Abstract][Full Text] [Related]
14. Omics sciences and precision medicine in Urothelial Carcinoma.
Medori MC; Micheletti C; Madeo G; Maltese PE; Tanzi B; Tezzele S; Mareso C; Generali D; Donofrio CA; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Beccari T; Ceccarini MR; Stuppia L; Stuppia L; Gatta V; Cristoni S; Ahmed R; Ahmed R; Cecchin S; Marceddu G; Bertelli M
Clin Ter; 2023; 174(Suppl 2(6)):1-10. PubMed ID: 37994743
[TBL] [Abstract][Full Text] [Related]
15. The Emerging Role of Proteomics in Precision Medicine: Applications in Neurodegenerative Diseases and Neurotrauma.
Alaaeddine R; Fayad M; Nehme E; Bahmad HF; Kobeissy F
Adv Exp Med Biol; 2017; 1007():59-70. PubMed ID: 28840552
[TBL] [Abstract][Full Text] [Related]
16. Bladder cancer: molecular determinants of personalized therapy.
Lopez-Beltran A; Santoni M; Massari F; Ciccarese C; Tortora G; Cheng L; Moch H; Scarpelli M; Reymundo C; Montironi R
Curr Drug Targets; 2015; 16(2):115-24. PubMed ID: 25654736
[TBL] [Abstract][Full Text] [Related]
17. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
Knepper TC; Bell GC; Hicks JK; Padron E; Teer JK; Vo TT; Gillis NK; Mason NT; McLeod HL; Walko CM
Oncologist; 2017 Feb; 22(2):144-151. PubMed ID: 28179575
[TBL] [Abstract][Full Text] [Related]
18. 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.
Hu J; Othmane B; Yu A; Li H; Cai Z; Chen X; Ren W; Chen J; Zu X
BMC Med; 2021 Nov; 19(1):289. PubMed ID: 34836536
[TBL] [Abstract][Full Text] [Related]
19. Individualized management of advanced bladder cancer: Where do we stand?
Burgess EF
Urol Oncol; 2015 Apr; 33(4):187-95. PubMed ID: 24332641
[TBL] [Abstract][Full Text] [Related]
20. Hope and challenge: Precision medicine in bladder cancer.
Su H; Jiang H; Tao T; Kang X; Zhang X; Kang D; Li S; Li C; Wang H; Yang Z; Zhang J; Li C
Cancer Med; 2019 Apr; 8(4):1806-1816. PubMed ID: 30907072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
